Government Struggles to Hold Opioid Manufacturers Accountable

For the first time ever, the U.S. DEA targeted a prescription drug manufacturer for their role in black market opioids and damages incurred. Mallinckrodt Pharmaceuticals, one of the largest national manufacturers of the highly addictive generic painkiller oxycodone, one of the leading drugs responsible for the more than 15,000 overdose deaths in 2015, was accused of shirking its responsibility to report suspicious drug orders.

Who’s to Blame For The Opioid Epidemic?

Created at Mallinckrodt’s Hobart, NY facility, oxycodone shipped via its distributor network, including KeySource, Sunrise Wholesale and Cardinal […]

By |July 24th, 2017|Clinical Alert, Drug Utilization Review, Pharmaceutical Industry|Comments Off on Government Struggles to Hold Opioid Manufacturers Accountable

Clinical Alert – Zohydro

CAansheaderZohydro® is a hydrocodone extended-release (ER) formulation recently approved by the FDA. The approval of Zohydro® has been so controversial that the Governor of Massachusetts attempted to ban the sale of Zohydro® in the state. The cost of Zohydro® ranges from a minimum of $420/Rx (for 10 mg twice daily; #60 capsules) to $514/Rx (for 50 mg twice daily; #60 capsules). Generic hydrocodone/APAP 5/325 mg #120 (dosed four times daily) only costs about $20/Rx. Practice guidelines and published review […]

By |May 6th, 2014|Clinical Alert|Comments Off on Clinical Alert – Zohydro